SIRPA and neoplasm: Assuming that progress can be made on clinically safe targeting of the macrophage checkpoint, to overcome some current issues, the results here also suggest interesting effects and possible benefits when combining cancer CIN with sufficient myeloid cells, disruption of CD47-SIRPα, and tumor opsonization.